Clinical trials: Tumor Angiogenesis
Refractory or Recurrent Solid Tumor
Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults
Immunotherapies have revolutionized medical oncology following the remarkable and, in some cases, unprecedented outcomes observed in certain groups of patients with cancer.
- Trial name
- SPARTO (NCT05210413)
- Testing
- Spartalizumab in Pediatric cohort, Low-dose Pazopanib in Pediatric Cohort, Spartalizumab in Adult cohort
- Where
- 13 sites in France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Bordeaux
Brain and Central Nervous System Tumors
Studying Cerebrospinal Fluid Proteins and Angiogenesis Proteins in Young Patients With Newly Diagnosed Central Nervous System Tumors
RATIONALE: Studying samples of cerebrospinal fluid from patients with cancer in the laboratory may help doctors identify biomarkers related to cancer.
- Trial name
- NCT00897858
- Where
- 8 sites in United States
- Sponsor
- Pediatric Brain Tumor Consortium
Ischemic Attack, Ischemic Stroke
Multiple Burrhole Therapy With Erythropoietin for Unstable Moyamoya
In this study, the investigators aim to evaluate the indirect revascularization outcomes of a new combination therapy of multiple burrhole procedure with promotion of arteriogenesis by intravenous (IV) erythropoietin (EPO)…
- Conditions
- Ischemic Attack, Ischemic Stroke, Moyamoya Disease, Burr Hole
- Trial name
- NCT03162588
- Testing
- erythropoietin
- Where
- South Korea
- Volunteers
- 37 people
- Sponsor
- Ajou University School of Medicine
Diffuse Intrinsic Pontine Glioma
A Phase II Study of Pegylated Interferon Alfa 2b (PEG-Intron(Trademark)) in Children With Diffuse Pontine Gliomas
Diffuse pontine gliomas are tumors on the pons portion of the brainstem. Their peak incidence is in children between 5 and 10 years old. Their location makes surgical resection impossible.
- Trial name
- NCT00036569
- Testing
- adjuvant therapy, pegylated interferon alfa
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- National Cancer Institute (NCI)
Non-small Cell Lung Cancer (NSCLC) Stage IV, Locally Advanced Non-Small Cell Lung Cancer
An Exploratory Clinical Study Of Bempemab Combined With Anlotinib As First-Line Treatment For Elderly Patients With Locally Advanced Or Metastatic Non-Small-Cell Lung Cancer
This exploratory clinical study evaluates the efficacy and safety of combining benmelstobart (a PD-L1 inhibitor) with anlotinib (a multi-target anti-angiogenic TKI) as a first-line, chemotherapy-free treatment for elderly…
- Conditions
- Non-small Cell Lung Cancer (NSCLC) Stage IV, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-small Cell Lung Cancer
- Trial name
- BEACON-OLD (NCT07849712)
- Testing
- Benmelstobart Combined With Anlotinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Zhejiang Cancer Hospital
Advanced Soft Tissue Sarcoma
A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma
The purpose of the phase 1b portion is to evaluate safety and tolerability and determine a recommended phase 2 dose for TRC105 when added to standard dose pazopanib in patients with advanced soft tissue sarcoma.
- Trial name
- NCT01975519
- Testing
- TRC105 and Pazopanib
- Where
- 9 sites in United States
- Volunteers
- 111 people
- Sponsor
- Tracon Pharmaceuticals Inc.
Osteosarcoma, Pulmonary Metastases
Pulmonary Resectable Metastases of Osteosarcoma With Anti-angiogenics and CHemotherapy
The aim of this study is to evaluate the efficacy and safety of Second-line chemotherapy combined with Apatinib for the patients with resectable pulmonary metastasis of osteosarcoma.
- Conditions
- Osteosarcoma, Pulmonary Metastases, Apatinib
- Trial name
- PROACH (NCT03742193)
- Testing
- Apatinib, GD regimen
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Ruijin Hospital
NSCLC (Advanced Non-small Cell Lung Cancer)
A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This is a Randomized, Double-Blind, Multicenter, Phase II/III Study to Evaluate HLX37 (Recombinant Human Anti-PD-L1 and Anti-VEGF Bispecific Antibody) in Combination with Chemotherapy Versus Pembrolizumab in Combination with…
- Trial name
- NCT07865910
- Testing
- Investigational drug: HLX37 dose1, IV, Q3W, PEMBROLIZUMAB (alone or when added to a regimen above), Carboplatin (Investigator discretion)
- Where
- 16 sites in China
- Volunteers
- 1,438 people
- Sponsor
- Shanghai Henlius Biotech
Retinopathy of Prematurity
Bevacizumab Eliminates the Angiogenic Threat for Retinopathy of Prematurity
The purpose of this study was to determine the efficacy and additional advantages of intravitreal bevacizumab in the treatment of ROP for both Zone I and Zone II Posterior.
- Trial name
- BEAT-ROP (NCT00622726)
- Testing
- Bevacizumab, Conventional Laser for ROP
- Where
- 15 sites in United States
- Volunteers
- 150 people
- Sponsor
- The University of Texas Health Science Center, Houston
Multiple Myeloma, Newly Diagnosed
Clinical Implication of Bone Marrow Perfusion Patterns Imaged by Dynamic MRI in Multiple Myeloma
Background: Multiple myeloma (MM) is a clonal plasma cell neoplasm characterized by proliferation of neoplastic plasma cells in bone marrow (BM).
- Trial name
- NCT00166855
- Testing
- dynamic MRI and bone marrow sampling
- Where
- Taiwan
- Volunteers
- 40 people
- Sponsor
- National Taiwan University Hospital
Ischemic Cardiopathy
Induced Angiogenesis by Genic Therapy in Advanced Ischemic Cardiomyopathy
Human Vascular Endothelial Grown Factor 165 (hVEGF165) administration is promising therapy induces a new vessels, arterioles and capillaries in regions whose revascularization surgery is not possible by direct or by percutaneous…
- Trial name
- THEANGIOGEN (NCT00744315)
- Testing
- Mini-thoracotomy for intramyocardial injection of VEGF165
- Where
- Brazil
- Volunteers
- 20 people
- Sponsor
- Instituto de Cardiologia do Rio Grande do Sul
Sarcoma, Alveolar Soft Part
Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
Background: Alveolar soft part sarcoma (ASPS) is a rare, highly vascular tumor accounting for less than 1% of soft tissue sarcomas. There is no effective systemic treatment for patients with metastatic ASPS.
- Trial name
- NCT01391962
- Testing
- Cediranib, Sunitinib, Prochlorperazine
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Retinopathy of Prematurity
Safety and Efficacy of Propranolol in Newborns With Retinopathy of Prematurity
The purpose of this study is to determine whether the administration of propranolol is effective in the treatment of the retinopathy of the prematurity.
- Trial name
- PROP-ROP (NCT01079715)
- Testing
- Propranolol
- Where
- 2 sites in Italy
- Volunteers
- 52 people
- Sponsor
- Meyer Children's Hospital IRCCS
Oral Cavity Cancer
A Study of High-Risk Oral Cavity Cancer
Objectives: 1. To study the effect of anti-angiogenesis therapy on reducing the recurrence of high-risk oral cavity cancer patients after curative local treatment. 2.
- Trial name
- NCT00934739
- Testing
- Thalidomide, Celebrex, Cyclophosphamide, Dexamethasone
- Volunteers
- 150 people
- Sponsor
- National Health Research Institutes, Taiwan
Myocardial Infarction
Myocardial Regeneration and Angiogenesis in Myocardial Infarction With G-CSF and Intra-Coronary Stem Cell Infusion
This trial was performed to evaluate the safety and the efficacy of G-CSF based stem cell therapy in patients with AMI. MAGIC Cell-1 trial enrolled patients with acute and old myocardial infarction, and had two groups of cell…
- Trial name
- NCT00307879
- Testing
- Drug: G-CSF (Dong-A pharmaceutical, Seoul, Korea), collection of mobilized peripheral blood stem cells, Intracoronary infusion of mobilized cells
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Seoul National University Hospital
Placenta Previa
Causal Relationship Between Plasma VEGF Family Proteins and Placenta Previa: A Two-Sample Mendelian Randomization Study
This study aims to investigate the causal relationship between plasma vascular endothelial growth factor (VEGF) family proteins and placenta previa using a two-sample Mendelian randomization (MR) approach.
- Trial name
- VEGF PP (NCT06620068)
- Volunteers
- 207,473 people
- Sponsor
- Guangzhou Institute of Respiratory Disease
Kidney Cancer, Metastatic Cancer
Ultrasound in Assessing Antiangiogenic Treatment in Patients With Advanced Kidney Cancer
RATIONALE: Diagnostic procedures, such as contrast-enhanced ultrasound, may help measure a patient's response to treatment with drugs such as sunitinib malate, sorafenib tosylate, or bevacizumab, and allow doctors to plan better…
- Trial name
- NCT01105364
- Testing
- antiangiogenesis therapy, stabilized sulphur hexafluoride microbubble-based contrast agent, imaging biomarker analysis
- Where
- France
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute, France
Colorectal Cancer
WT1 in Colorectal Adenocarcinoma
Colorectal carcinoma is a major bublic health problem. It is due to several genetic mutations. Wilms' tumor1 (WT1) gene is a tumor suppressor gene that has been mutated in several human tumors.
- Trial name
- NCT07778628
- Testing
- immunohistochemical staining with WT1 antibody
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Sohag University
Carcinoma, Renal Cell
REGISTRY OF COMPLETE RESPONSES TO SUNITINIB IN SPANISH PATIENTS WITH METASTATIC RENAL CELL CARCINOMA
Observational, retrospective, multicentre study in spanish patients with metastatic Renal Cell Carcinoma (mRCC) treated with sunitinib as a first-line treatment (treatment with previous cytokine therapy is accepted) according to…
- Trial name
- ATILA (NCT03916458)
- Where
- 31 sites in Spain
- Volunteers
- 62 people
- Sponsor
- Pfizer